Results 211 to 220 of about 69,334 (300)

Orientation of Gp96 and Calreticulin T-cell epitopes in a multiepitope HPV16 E7 vaccine construct affects predicted immunostimulatory properties: An in silico and expression validation study. [PDF]

PLoS One
Esmail Nia G, Shahosseini Z, Akbari E, Bamehr H, Heidarnejad F, Mohsenzadegan M, Bolhassani A, Farajollahi M.   +7 more
europepmc   +1 more source

Characterization of Immune Responses to RBD‐SD1 Nanoparticle Vaccines Derived From ACE2‐Capable HKU5‐CoV‐2, NeoCoV, and HKU5 Merbecoviruses

Biotechnology and Bioengineering, EarlyView.
SpyCatcher‐mi3 nanoparticles presenting HKU5, NeoCoV, and HKU5‐CoV‐2 RBD‐SD1 induced strong, cross‐reactive IgG responses in immunized mice. The surrogate virus neutralization test demonstrated strong activity in sera from homologous vaccination. ABSTRACT Recent discoveries of merbecoviruses such as HKU5, NeoCoV, and HKU5‐CoV‐2 that use angiotensin ...
Peter J. Halfmann, Jeong Soo Lee, Augustine Duffy, Tong Wang, Bingcheng Huang, James Z. Kurdi, Ajay Inampudi, Natasha Chen, Elizabeth Frimpong, Carmen Rai, Yoshihiro Kawaoka, Ravi S. Kane   +11 more
wiley   +1 more source

Licensed and investigational TLR4 agonists as vaccine adjuvants: structural basis, clinical progress, and future directions. [PDF]

Front Immunol
Zhou J, Liu B, Yang Q, Zhou J, Zheng J, Chen Y, Fu L, Du J, Zhang Z, Zhang J, Li C.   +10 more
europepmc   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

Biotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga, Udisha Singh, Sachin Dattram Pawar   +2 more
wiley   +1 more source

An Engineered Nano-Vesicle Adjuvant Platform (ENAP) for Cytokine Delivery Enables a Novel Antigen-Coordinated Vaccine Against Helicobacter pylori. [PDF]

J Extracell Vesicles
Shang Y, Zhang X, Li L, Yu X, Zeng L, Cao Y, Tao Z, Shen L, Zhang S, Yang C, Tian H, Liang Y, Liao H, Huang X, Liu Q.   +14 more
europepmc   +1 more source

Transcriptomic and proteomic signatures following AS03-adjuvanted Influenza A/H7N9 vaccine. [PDF]

Front Immunol
Creech CB, Steenbergen KJ, Gelber CE, Howard LM, Schey KL, Rose KL, Yoder SM, Edwards KM, Goll JB.   +8 more
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Programmable Antigen-Specific Immunity via Self-Adjuvanting Nanovaccines Co-Delivering Immune Modulators. [PDF]

Angew Chem Int Ed Engl
Ito K, Manabe Y, Ohshima S, Maeki M, Tokeshi M, Inaba H, Matsuura K, Kabayama K, Kametani Y, Fukase K.   +9 more
europepmc   +1 more source

Targeting neutrophil extracellular traps in metabolic and immune niche: Nanomaterials for diabetes tissue regeneration

BMEMat, EarlyView.
The effects of NETs on regeneration of various diabetic tissues, and strategies targeting NETs for diabetes tissue regeneration. In the diabetic environment, NETs undergo complex metabolic and immune reprogramming, leading to dynamic changes in antibacterial and proinflammatory functions, and affecting regeneration of multiple systemic tissues.
Xinyi Jiang, Muxin Yue, Kai Mao, Boon Chin Heng, Noor Azlin Yahya, Yunsong Liu, Zheng Li   +6 more
wiley   +1 more source

Rational design of next-generation vaccine adjuvants: From molecular mechanisms to hybrid delivery platforms. [PDF]

Hum Vaccin Immunother
Zhao Y, Li J, Chen J, Yang C, Tao J, Zhu R.   +5 more
europepmc   +1 more source